广发证券股份有限公司 关于厦门金达威集团股份有限公司 2025 年度持续督导培训工作报告 保荐机构名称：广发证券股份有限公司 上市公司名称：厦门金达威集团股份有 限公司 保荐代表人姓名：孙昭伟 联系电话：021-38003800 保荐代表人姓名：李姝 联系电话：021-38003800 培训实施人员姓名：李姝 参加培训人员：公司董事、高级管理人员、财务部、内审部等相关人员 培训时间：2025 年 9 月 8 日 培训对应期间：2025 年度 培训主要内容：上市公司募集资金管理重点事项及监管案例介绍 一、培训基本情况 2025 年 9 月 8 日，广发证券股份有限公司（以下简称"广发证券"或"保 荐机构"）对厦门金达威集团股份有限公司（以下简称或"公司"）进行了持续督 导专项培训，培训内容包括上市公司募集资金管理重点事项及监管案例介绍 等。公司董事、高级管理人员、财务部、内审部等相关人员参加了此次培训。 二、培训内容简介 广发证券本次培训主要围绕上市公司募集资金监管规则等相关要求，在规范 募集资金使用等方面做了讲解和说明，并结合相关监管案例，传达了中国证监会、 深圳证券交易所等监管机构的最新监管动向。 三、培训 ...

Group 1 - The company has completed 90% of the expansion project for coenzyme Q10 as of the first half of the year [2] - The project is currently in the final stages and is gradually ramping up production capacity [2] - Once fully operational, the annual production capacity for coenzyme Q10 will reach 920 tons [2]

Core Viewpoint - Jindawei announced that its subsidiary, Jiangsu Chengxin Pharmaceutical Co., Ltd., has received a veterinary drug product approval number from the Ministry of Agriculture and Rural Affairs of the People's Republic of China [2] Group 1 - The approval signifies a regulatory milestone for the company in the veterinary pharmaceutical sector [2] - This development may enhance the company's product portfolio and market competitiveness [2] - The approval could lead to potential revenue growth from the veterinary drug market [2]

Group 1 - Dematech won a 900 million yuan overseas smart logistics project from a well-known e-commerce giant in Latin America, focusing on intelligent logistics cross-belt sorting systems and related services [1] - Kang En Bei received approval for the registration of short-term financing bonds and medium-term notes, with a total registration amount of 1 billion yuan, valid for two years [1][2] - Zhi Xiang Jin Tai's GR1803 injection for systemic lupus erythematosus clinical trial has been approved by the National Medical Products Administration [2] Group 2 - Jin Da Wei's subsidiary received approval for a veterinary drug product, pyridone, valid from September 3, 2025, to September 2, 2030 [4] - Fu Li Wang's subsidiary plans to invest 500 million yuan in a high-end wire material project, focusing on high-strength prestressed steel strands for various applications [5] - He Li Biological's subsidiary's Class III medical device registration application has been accepted, focusing on natural bone repair materials [12] Group 3 - Lin Yang Energy won a 244 million yuan metering equipment project from Southern Power Grid, expected to positively impact its 2025 and 2026 performance [20] - Sanxia Water plans to absorb its wholly-owned subsidiary, Chongqing Changdian United Energy, with all assets and liabilities to be inherited by Sanxia Water [13] - Tian Cheng Technology canceled the use of 91 million yuan of raised funds for permanent working capital, ensuring no impact on the normal operation of investment projects [24] Group 4 - Baosteel received approval to publicly issue bonds totaling 20 billion yuan to professional investors, valid for 24 months [52] - Tian Kang Biological reported a 10.15% year-on-year increase in pig sales in August, with a total of 263,800 pigs sold [53] - Xinjiang Construction won multiple major projects totaling 4.506 billion yuan, including a 2.4 billion yuan photovoltaic hydrogen synthesis project [18]

Core Viewpoint - The company, Jindawei (002626.SZ), announced that its subsidiary, Jiangsu Chengxin Pharmaceutical Co., Ltd., has received a veterinary drug approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the product Pyrantel, with the approval number 102091173 [1] Group 1 - The approval signifies a regulatory milestone for the company in the veterinary pharmaceutical sector [1] - The product Pyrantel is expected to enhance the company's product portfolio and market presence in the veterinary medicine industry [1]

| 证券代码：002626 | 证券简称：金达威 | 公告编号：2025-082 | | --- | --- | --- | | 债券代码：127111 | 债券简称：金威转债 | | 厦门金达威集团股份有限公司 关于控股子公司取得兽药产品批准文号批件的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 兽药产品批准文号：兽药原字 102091173 发证日期：2025 年 9 月 3 日 有效期：2025 年 9 月 3 日至 2030 年 9 月 2 日 此次获得兽药产品批准文号批件，能提升公司产品的市场竞争力，预计不会 对公司本年度经营业绩产生重大影响，请注意投资风险。 特此公告。 厦门金达威集团股份有限公司 董 事 会 厦门金达威集团股份有限公司（以下简称"公司"）控股子公司江苏诚信药 业有限公司，近日收到中华人民共和国农业农村部颁发的兽药产品批准文号批件， 具体情况如下： 企业名称：江苏诚信药业有限公司 生产地址：启东滨江精细化工园区 通用名称：吡喹酮 二〇二五年九月十日 ...

Core Viewpoint - The company Jindawei (002626) announced that its subsidiary Jiangsu Chengxin Pharmaceutical Co., Ltd. has received the veterinary drug approval number from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the product with the generic name Praziquantel [1] Company Summary - Jindawei's subsidiary Jiangsu Chengxin Pharmaceutical has obtained a significant regulatory approval, which may enhance its product portfolio and market presence in the veterinary drug sector [1]

Group 1: Overall Business Performance - In the first half of 2025, the company's total revenue reached 17.28 billion yuan, a 13.46% increase compared to the same period last year [2] - The net profit attributable to shareholders was 90.12 million yuan, reflecting a 2.47% growth year-on-year [2] Group 2: Nutritional Raw Materials Business - The company specializes in the large-scale production of products such as Coenzyme Q10, DHA, ARA, NMN, and Vitamin K2, among others [3] - Coenzyme Q10 holds the largest global market share, with a significant increase in gross margin due to production scale effects and technological improvements [3] - The company is investing in new product development using synthetic biology and microbial fermentation technologies [3] Group 3: Coenzyme Q10 Business - Coenzyme Q10 is increasingly recognized for its health benefits, leading to a growing market demand, particularly in China due to aging population and upgraded health awareness [3] - The company is the largest global producer of Coenzyme Q10, exporting to numerous countries and regions [3] - Expansion plans are in place to meet the rising market demand and strengthen the company's leading position in the industry [3] Group 4: Nutritional Supplements Business - The company owns several brands, including Doctor's Best and Zipfizz, with production services provided by its U.S. subsidiary, VitaBest [4] - Sales of Doctor's Best and Zipfizz experienced a decline in the first half of 2025 due to inventory control and purchasing adjustments by downstream customers [5] - The company is focusing on brand building and enhancing marketing efforts to improve sales channels and brand influence [5] Group 5: Domestic Nutritional Supplements Business - The domestic market for nutritional supplements is primarily served through online channels like Tmall and JD.com, with growth driven by the increasing demand for cross-border e-commerce [5] - The company aims to enhance operational efficiency and expand its market share in domestic self-owned brands [5]

证券日报网讯 9月9日晚间，金达威发布公告称，公司第九届董事会第六次会议审议通过了《关于聘任 副总经理、董事会秘书的议案》等多项议案。 （文章来源：证券日报） ...

Group 1 - The company announced the appointment of Li Xiaofang as the new Vice President and Board Secretary [2] - The decision was made during the sixth meeting of the ninth board of directors held on September 9, 2025 [2] - The term of the new appointment will last until the end of the current board's term [2]